Mangoceuticals loss doubles to $20.6M; auditor flags going-concern, capital insufficient for 12 months

Filed April 1, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 20, 2025 · ~2 min read

Key Changes

• high

  Net loss surged to $8,707,226 in FY2025 from $11,823,899 in FY2024, driven by revenue decline, higher G&A, and stock-based compensation that jumped 358% to $10.8 million. Auditor included going-concern language in FY2025 report.

  MD&A: Financial Results verify on EDGAR →
• high

  Management reversed prior-year liquidity assessment: current capital resources now deemed insufficient for next 12 months, versus prior year's statement that capital was sufficient. Company must raise additional funding to continue operations.

  MD&A: Going Concern verify on EDGAR →
• high

  Working capital improved from $1.3 million deficit to $0.6 million positive, aided by December 2025 registered direct offering that raised $2.5 million gross. Equity Line of Credit exhausted after raising only $1.8 million of $25 million commitment.

  MD&A: Liquidity verify on EDGAR →